This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Glaxosmithkline (GSK.L) – U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally. Closing Price 1463.00p. (Reuters)
Glencore (GLEN.L) – Will hold talks with the government of the Australian state of Queensland over developing vast bauxite reserves that have remained untapped for decades despite a series of attempts by mining companies to get a project off the ground. Closing Price 366.75p. (Reuters)
Gulf Keystone Petroleum (GKP.L) – Revenues of $18.7m in H1; additional revenue of $35m owed crude oil export sales. Loss after tax $29.8m. Net proceeds of $240m raised from the issue of debt securities and associated warrants. Cash and equivalents of $177m. Closing Price 82.75p (Investegate)
Lamprell (LAM.L) – Operating profit nearly tripled as it completed four major projects ahead of budget in the first half of the year. Reports an operating profit of $53.4m in the six months ended June 30, compared with $19.2m a year earlier. Revenue rose 25% to $632.3m. Closing Price 156.25p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| Evraz | EVR.L | -0.44% | 0.97% | -3.86% |
| Foxtons | FOXT.L | -9.40% | 0.55% | -11.18% |
| Glencore | GLEN.L | 0.96% | 1.46% | -0.36% |
| BHP Billiton | BLT.L | 0.10% | 0.93% | -0.24% |
| Royal Bank of Scotland | RBS.L | 0.19% | 0.63% | -0.81% |
| 888 Holdings | 888.L | -0.38% | 5.25% | -2.17% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research